NASDAQ:COLL

Collegium Pharmaceutical Stock Insider Trading

NASDAQ Stock Exchange > Healthcare > Drug Manufacturers - Specialty & Generic

$37.72

+1.08 (+2.95%)

At Close: Oct 11, 2024

Collegium Pharmaceutical Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 1.95. In total, the insiders bought 1 343 698 and sold 1 159 781 COLL shares in the last 100 trades.

Insider Power (Last 100 transactions)	1.95
Buy	1 343 698 Shares
Sell	1 159 781 Shares

Historical Insider Trades

Date	Type	Action	Person	Amount
Sep 13, 2024	Common Stock	Sell	Smith Thomas B	9 593
Sep 06, 2024	Common Stock	Sell	Kuhlmann Shirley R.	977
Sep 05, 2024	Common Stock	Sell	Kuhlmann Shirley R.	16 848
Sep 05, 2024	Common Stock	Sell	Kuhlmann Shirley R.	2 400
Jun 03, 2024	Common Stock	Sell	Kuhlmann Shirley R.	24 300
Jun 03, 2024	Common Stock	Sell	Kuhlmann Shirley R.	700
May 28, 2024	Common Stock	Sell	Tupper Colleen	19 710
May 24, 2024	Common Stock	Buy	Dreyer Scott	23 791
May 24, 2024	Common Stock	Sell	Dreyer Scott	56 807
May 24, 2024	Stock Option (Right to Purchase)	Sell	Dreyer Scott	23 791
May 23, 2024	Common Stock	Buy	Dreyer Scott	51 209
May 23, 2024	Common Stock	Sell	Dreyer Scott	51 209
May 23, 2024	Stock Option (Right to Purchase)	Sell	Dreyer Scott	51 209
May 16, 2024	Common Stock	Buy	Santini Gino	7 693
May 16, 2024	Common Stock	Buy	Melincoff Gwen A	7 693
May 16, 2024	Common Stock	Buy	Mcfarlane Neil F.	7 693
May 16, 2024	Common Stock	Buy	Freund John Gordon	7 693
May 16, 2024	Common Stock	Buy	Fallon John A.	7 693
May 16, 2024	Common Stock	Buy	Balice-gordon Rita J.	7 693
May 16, 2024	Common Stock	Buy	Heffernan Michael Thomas	7 693
May 16, 2024	Common Stock	Buy	Bohlin Garen G	7 693
May 14, 2024	Common Stock	Buy	Bohlin Garen G	28 985
May 14, 2024	Common Stock	Sell	Bohlin Garen G	28 985
May 14, 2024	Stock Option (Right to Purchase)	Sell	Bohlin Garen G	28 985
Feb 29, 2024	Common Stock	Sell	Smith Thomas B	995

ABOUT COLLEGIUM PHARMACEUTICAL

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatm...

Read Full Profile Here